Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

By afschroeder • September 17, 2026

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study. J Am Acad Dermatol. 2026 Sep 16:S0190-9622(26)03548-6. doi: 10.1016/j.jaad.2026.09.040. Epub ahead of print. PMID: 42749063.

Tags: clinical research, Dermatology, ixekizumab, psoriasis, psoriatic arthritis, Publications, Treat-to-target

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]

Xenium spatial transcriptomics identifies mesenchymal fibroblast expansion and conserved fibrotic ECM programs in keloid

Deng M, Brewer GM, Espinoza A, Orellana-Montes J, Hedayatyanfard K, Hu C, Jahan MGS, Deriss M, Davis JC, Cheng CE, Pellegrini M, Agak GW. Xenium[...]